Clinical trial
Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)
NCT00464919 · National Taiwan University Hospital, Other · Completed
Key facts
| NCT number | NCT00464919 |
|---|---|
| Title | Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC) |
| Official title | A Phase II Study of Sorafenib Plus Tegafur/Uracil for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma |
| Lead sponsor | National Taiwan University Hospital, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | Sorafenib, tegafur/uracil (UFUR®) |
| Enrollment | 50 |
| Start date | Apr 1, 2007 |
| Completion | Mar 1, 2009 |
| First posted | Apr 24, 2007 |
| Last update posted | Jul 7, 2009 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: